Novel disease-specific promoters for use in gene therapy for Parkinson's disease.
Elgstrand, Erika LU ; Gussing, Fredrik LU ; Quintino, Luis LU
and Lundberg, Cecilia
LU
(2012)
In Neuroscience Letters
530(1).
p.29-34
- Abstract
- Gene therapy is a promising therapeutic tool for Parkinson's disease (PD), but there is a lack of evaluated cell specific promoters that are relevant for the disease. We have chosen PD relevant promoter candidates for gene therapy vectors based on either previous studies; Drd1a, Drd2 and pDyn, or from a microarray study on parkinsonian patients; ACE, DNAJC3, GALNS, MAP1a and RNF25. These candidates have been evaluated in rat striatum to determine their suitability for use in cell specific vectors. The promoters had a neuronal specificity of 91-100%. The efficiency of the promoters was variable, but RNF25, DNAJC3 and MAP1a were comparable to widely used ubiquitous promoters. MAP1a was also affected by dopamine depletion.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/3160760
- author
- Elgstrand, Erika
LU
; Gussing, Fredrik
LU
; Quintino, Luis
LU
and Lundberg, Cecilia
LU
- organization
- publishing date
- 2012
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Promoter, Parkinson's disease, Gene therapy, Neuron-specific
- in
- Neuroscience Letters
- volume
- 530
- issue
- 1
- pages
- 29 - 34
- publisher
- Elsevier
- external identifiers
-
- wos:000311664000006
- pmid:23063686
- scopus:84868301718
- pmid:23063686
- ISSN
- 0304-3940
- DOI
- 10.1016/j.neulet.2012.09.059
- language
- English
- LU publication?
- yes
- id
- 39771ee8-f471-417a-9f7a-905468f9ee0f (old id 3160760)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/23063686?dopt=Abstract
- date added to LUP
- 2016-04-01 10:03:47
- date last changed
- 2022-02-09 22:17:39
@article{39771ee8-f471-417a-9f7a-905468f9ee0f,
abstract = {{Gene therapy is a promising therapeutic tool for Parkinson's disease (PD), but there is a lack of evaluated cell specific promoters that are relevant for the disease. We have chosen PD relevant promoter candidates for gene therapy vectors based on either previous studies; Drd1a, Drd2 and pDyn, or from a microarray study on parkinsonian patients; ACE, DNAJC3, GALNS, MAP1a and RNF25. These candidates have been evaluated in rat striatum to determine their suitability for use in cell specific vectors. The promoters had a neuronal specificity of 91-100%. The efficiency of the promoters was variable, but RNF25, DNAJC3 and MAP1a were comparable to widely used ubiquitous promoters. MAP1a was also affected by dopamine depletion.}},
author = {{Elgstrand, Erika and Gussing, Fredrik and Quintino, Luis and Lundberg, Cecilia}},
issn = {{0304-3940}},
keywords = {{Promoter; Parkinson's disease; Gene therapy; Neuron-specific}},
language = {{eng}},
number = {{1}},
pages = {{29--34}},
publisher = {{Elsevier}},
series = {{Neuroscience Letters}},
title = {{Novel disease-specific promoters for use in gene therapy for Parkinson's disease.}},
url = {{http://dx.doi.org/10.1016/j.neulet.2012.09.059}},
doi = {{10.1016/j.neulet.2012.09.059}},
volume = {{530}},
year = {{2012}},
}